In short
Tobramycin sulfate is an aminoglycoside antibiotic, a type of medicine that kills certain bacteria. It is already used in authorised medicines, for example as an inhaled solution for people with cystic fibrosis. In the ABOGRAFT trial, researchers are studying whether placing tobramycin directly into the hip joint during replacement surgery can reduce the risk of a serious infection called prosthetic joint infection. This phase 2 trial plans to enrol 1,400 people.
Key points
- Tobramycin sulfate is an aminoglycoside antibiotic produced by Streptomyces strains.
- The ABOGRAFT trial is a phase 2 study testing tobramycin in prosthetic joint infection prevention.
- The trial plans to enrol 1,400 participants undergoing hip replacement surgery.
- Tobramycin is given directly into the joint (intra-articular use) in this study.
- The main outcome is reoperation due to infection within two years after hip arthroplasty.
- Tobramycin is already authorised in forms such as nebuliser solution and oral solution.
What is tobramycin sulfate?
Tobramycin sulfate is an aminoglycoside antibiotic, a broad-spectrum medicine that belongs to a class of drugs produced by Streptomyces strains. It is known under several trade names, including Tobi, Tobrex, Bethkis, and Vantobra. The substance is already authorised as a medicine in several forms, including a nebuliser solution for inhalation and an oral solution. Its chemical formula is C18H37N5O9, and it is classified under ATC code J01GB01 as an antibacterial.
How does tobramycin sulfate work?
Tobramycin works by inhibiting protein biosynthesis in bacteria, which means it stops bacteria from making the proteins they need to survive and multiply. As an aminoglycoside antibiotic, it has a broad spectrum of activity against different types of bacteria. In the ABOGRAFT trial, tobramycin is being studied together with vancomycin, another antibiotic, to see whether the combination can reduce the risk of infection after hip replacement surgery.
Which conditions is tobramycin sulfate used or studied for?
- Prosthetic joint infection — the ABOGRAFT trial is studying whether tobramycin placed in the hip joint during replacement surgery can prevent this serious infection.
- Cystic fibrosis — tobramycin is used as an inhaled medicine in people with cystic fibrosis who have Pseudomonas aeruginosa lung infections.
How is tobramycin sulfate given?
Tobramycin sulfate is available in several pharmaceutical forms. There is a nebuliser solution for inhalation use, with a strength of 300 mg per 5 ml, authorised in several European Union countries. An oral solution containing 20 mg per 5 ml is also listed as a prescribable product. In the ABOGRAFT trial, tobramycin is given directly into the joint space (intra-articular use) at a dose of 1920 mg/ml, mixed into a bone graft.
What do the clinical trials show?
One registered clinical trial, the ABOGRAFT trial, is investigating tobramycin sulfate for the prevention of prosthetic joint infection. It is a phase 2 interventional study that plans to enrol 1,400 participants undergoing hip replacement surgery. Participants are treated with an antibiotic-impregnated bone graft containing tobramycin and vancomycin, or a placebo-impregnated bone graft as a comparison. The primary outcome is reoperation due to infection, or a diagnosed prosthetic joint infection with bacteria sensitive to either antibiotic, within two years after surgery. The trial is currently authorised, meaning it has received regulatory approval to proceed.
What side effects are known?
The sources provided do not include a detailed list of side effects for tobramycin sulfate. Aminoglycoside antibiotics as a class are known to have potential effects on the kidneys and hearing, but specific side effect information for this substance is not available in the provided sources.